These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

143 related items for PubMed ID: 12941708

  • 1. Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect.
    Satoh N, Ogawa Y, Usui T, Tagami T, Kono S, Uesugi H, Sugiyama H, Sugawara A, Yamada K, Shimatsu A, Kuzuya H, Nakao K.
    Diabetes Care; 2003 Sep; 26(9):2493-9. PubMed ID: 12941708
    [Abstract] [Full Text] [Related]

  • 2. Mechanisms of early insulin-sensitizing effects of thiazolidinediones in type 2 diabetes.
    Tonelli J, Li W, Kishore P, Pajvani UB, Kwon E, Weaver C, Scherer PE, Hawkins M.
    Diabetes; 2004 Jun; 53(6):1621-9. PubMed ID: 15161771
    [Abstract] [Full Text] [Related]

  • 3. Differential regulations of lipid profiles between Japanese responders and nonresponders treated with pioglitazone.
    Kutoh E.
    Postgrad Med; 2011 Jan; 123(1):45-52. PubMed ID: 21293083
    [Abstract] [Full Text] [Related]

  • 4. Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients.
    Miyazaki Y, Mahankali A, Wajcberg E, Bajaj M, Mandarino LJ, DeFronzo RA.
    J Clin Endocrinol Metab; 2004 Sep; 89(9):4312-9. PubMed ID: 15356026
    [Abstract] [Full Text] [Related]

  • 5. The ratio of leptin to adiponectin can be used as an index of insulin resistance.
    Oda N, Imamura S, Fujita T, Uchida Y, Inagaki K, Kakizawa H, Hayakawa N, Suzuki A, Takeda J, Horikawa Y, Itoh M.
    Metabolism; 2008 Feb; 57(2):268-73. PubMed ID: 18191059
    [Abstract] [Full Text] [Related]

  • 6. Effect of pioglitazone on serum concentrations of osteoprotegerin in patients with type 2 diabetes mellitus.
    Park JS, Cho MH, Nam JS, Yoo JS, Ahn CW, Cha BS, Kim KR, Lee HC.
    Eur J Endocrinol; 2011 Jan; 164(1):69-74. PubMed ID: 20961967
    [Abstract] [Full Text] [Related]

  • 7. Arterial elasticity and plasma levels of adiponectin and leptin in type 2 diabetic patients treated with thiazolidinediones.
    Oz O, Tuncel E, Eryilmaz S, Fazlioglu M, Gul CB, Ersoy C, Ocak N, Dirican M, Cangur S, Baran I, Imamoglu S.
    Endocrine; 2008 Feb; 33(1):101-5. PubMed ID: 18392690
    [Abstract] [Full Text] [Related]

  • 8. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.
    Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Ragonesi PD, Querci F, Franzetti IG, Gadaleta G, Ciccarelli L, Piccinni MN, D'Angelo A, Cicero AF.
    Metabolism; 2010 Jun; 59(6):887-95. PubMed ID: 20015525
    [Abstract] [Full Text] [Related]

  • 9. Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone.
    Derosa G, D'Angelo A, Salvadeo SA, Ferrari I, Gravina A, Fogari E, Maffioli P, Cicero AF.
    Metabolism; 2008 Nov; 57(11):1552-7. PubMed ID: 18940393
    [Abstract] [Full Text] [Related]

  • 10. Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients.
    Miyazaki Y, DeFronzo RA.
    Diabetes Obes Metab; 2008 Dec; 10(12):1204-11. PubMed ID: 18476983
    [Abstract] [Full Text] [Related]

  • 11. [Effect of pioglitazone, one of TZDs, on IGT-patients].
    Kobayashi M.
    Nihon Rinsho; 2005 Feb; 63 Suppl 2():462-70. PubMed ID: 15779423
    [No Abstract] [Full Text] [Related]

  • 12. Antihypertensive and vasculo- and renoprotective effects of pioglitazone in genetically obese diabetic rats.
    Yoshimoto T, Naruse M, Nishikawa M, Naruse K, Tanabe A, Seki T, Imaki T, Demura R, Aikawa E, Demura H.
    Am J Physiol; 1997 Jun; 272(6 Pt 1):E989-96. PubMed ID: 9227442
    [Abstract] [Full Text] [Related]

  • 13. Short-term pioglitazone treatment improves vascular function irrespective of metabolic changes in patients with type 2 diabetes.
    Martens FM, Visseren FL, de Koning EJ, Rabelink TJ.
    J Cardiovasc Pharmacol; 2005 Dec; 46(6):773-8. PubMed ID: 16306801
    [Abstract] [Full Text] [Related]

  • 14. A randomized comparison of pioglitazone to inhibit restenosis after coronary stenting in patients with type 2 diabetes.
    Nishio K, Sakurai M, Kusuyama T, Shigemitsu M, Fukui T, Kawamura K, Itoh S, Konno N, Katagiri T.
    Diabetes Care; 2006 Jan; 29(1):101-6. PubMed ID: 16373904
    [Abstract] [Full Text] [Related]

  • 15. Clinical effectiveness and safety evaluation of long-term pioglitazone treatment for erythropoietin responsiveness and insulin resistance in type 2 diabetic patients on hemodialysis.
    Abe M, Okada K, Maruyama T, Maruyama N, Soma M, Matsumoto K.
    Expert Opin Pharmacother; 2010 Jul; 11(10):1611-20. PubMed ID: 20540652
    [Abstract] [Full Text] [Related]

  • 16. Lower plasma adiponectin concentration predicts the efficacy of pioglitazone in diabetic patients.
    Hiramatsu S, Tajiri Y, Karashima T.
    Diabetes Obes Metab; 2004 May; 6(3):231-3. PubMed ID: 15056132
    [Abstract] [Full Text] [Related]

  • 17. Pharmacodynamic Effects of Low-Dose Pioglitazone in Patients with the Metabolic Syndrome without Diabetes Mellitus.
    Vu A, Kosmiski LA, Beitelshees AL, Prigeon R, Sidhom MS, Bredbeck B, Predhomme J, Deininger KM, Aquilante CL.
    Pharmacotherapy; 2016 Mar; 36(3):252-62. PubMed ID: 26822630
    [Abstract] [Full Text] [Related]

  • 18. Effects of pioglitazone and metformin on plasma adiponectin in newly detected type 2 diabetes mellitus.
    Sharma PK, Bhansali A, Sialy R, Malhotra S, Pandhi P.
    Clin Endocrinol (Oxf); 2006 Dec; 65(6):722-8. PubMed ID: 17121522
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.